Breast cancer proteomics: clinical perspectives

Abstract

Breast cancer is the one of leading causes of cancer-related deaths in women within economically developed regions of the world. A major focus of present research into this malignancy is the identification of new biomarkers and drug targets to improve detection and treatment. Proteomics represents one of the latest technological developments in this context. It aims to analyse the complex circuitry of the breast cancer proteome. Here, the authors review how breast cancer proteomics has progressed so far, with emphasis on its potential application to clinically relevant scenarios.

Keywords::

• biomarkers
• breast cancer
• proteomics
• translational research

Acknowledgements

The authors acknowledge F Lanigan, J Byrne, A Byrne, I Miller and A Clarke for images used in Figure 1. Funding is acknowledged from the Health Research Board of Ireland, the latter under the auspices of the ‘Breast Cancer Metastasis: Biomarkers and Functional Mediators’ Research Programme. The UCD Conway Institute is funded by the Programme for Third Level Institutions (PRTLI), as administered by the Higher Education Authority (HEA) of Ireland.

Notes